y 27632 has been researched along with pioglitazone in 4 studies
| Studies (y 27632) | Trials (y 27632) | Recent Studies (post-2010) (y 27632) | Studies (pioglitazone) | Trials (pioglitazone) | Recent Studies (post-2010) (pioglitazone) |
|---|---|---|---|---|---|
| 1,924 | 3 | 891 | 4,338 | 824 | 2,277 |
| Protein | Taxonomy | y 27632 (IC50) | pioglitazone (IC50) |
|---|---|---|---|
| CDGSH iron-sulfur domain-containing protein 1 | Rattus norvegicus (Norway rat) | 1 | |
| Bile salt export pump | Rattus norvegicus (Norway rat) | 2 | |
| Peroxisome proliferator-activated receptor gamma | Rattus norvegicus (Norway rat) | 0.7 | |
| Bile salt export pump | Homo sapiens (human) | 0.337 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 0.114 | |
| Steryl-sulfatase | Homo sapiens (human) | 0.8 | |
| Peroxisome proliferator-activated receptor alpha | Mus musculus (house mouse) | 1.15 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.298 | |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 3.0379 | |
| Peroxisome proliferator-activated receptor gamma | Mus musculus (house mouse) | 0.7 | |
| CDGSH iron-sulfur domain-containing protein 2 | Homo sapiens (human) | 4.8 | |
| CDGSH iron-sulfur domain-containing protein 1 | Homo sapiens (human) | 8.65 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Atkins, KB; Brosius, FC; Irey, B; Xiang, N | 1 |
| Baharvand, H; Ghaedi, K; Ghoochani, A; Hashemi, MS; Kajabadi, NS; Kiani-Esfahani, A; Nasr-Esfahani, MH; Peymani, M | 1 |
4 other study(ies) available for y 27632 and pioglitazone
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A rapid, PPAR-gamma-dependent effect of pioglitazone on the phosphorylation of MYPT.
Topics: Amides; Anilides; Animals; Cells, Cultured; Cyclic AMP-Dependent Protein Kinases; Cyclic GMP-Dependent Protein Kinases; Enzyme Inhibitors; Hypoglycemic Agents; Muscle, Smooth, Vascular; Myosin-Light-Chain Kinase; Phosphorylation; Pioglitazone; PPAR gamma; Protein Phosphatase 1; Pyridines; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; Signal Transduction; Thiazolidinediones; Threonine | 2009 |
The Synergistic Enhancement of Cloning Efficiency in Individualized Human Pluripotent Stem Cells by Peroxisome Proliferative-activated Receptor-γ (PPARγ) Activation and Rho-associated Kinase (ROCK) Inhibition.
Topics: Amides; Clone Cells; Humans; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Pluripotent Stem Cells; Pyridines; rho-Associated Kinases; Signal Transduction; Thiazolidinediones | 2015 |